Evidence map›Paper›PMID 11309634›Full record

ArticleThe New England journal of medicine2001

Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

T Watanabe, T T Wu, P J Catalano, T Ueki, R Satriano, D G Haller, A B Benson, S R Hamilton

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
264citing papers in PubMed, 4 pooled it
36.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

264 citing papers in PubMed, 4 syntheses or guidelines pooled it, 894 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. The edible ethanol extract ofNutrition research and practice · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

204 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

T WatanabeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.
T T Wu
P J Catalano
T Ueki
R Satriano
D G Haller
A B Benson
S R Hamilton
Dana-Farber Cancer Institute · USJohns Hopkins University · USRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityThe University of Texas MD Anderson Cancer Center · USUniversity of Pennsylvania · US

Funding

ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
PROVIDE STATISTICAL SERVICESU10CA023318 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, ROBERT J · 1985 to 2013
$33.4M
MOLECULAR GENETICS AND ADJUVANT THERAPY OF COLON CANCERU01CA060100 · NCI · JOHNS HOPKINS UNIVERSITY · PI HAMILTON, STANLEY R · 1993 to 1996
–
NCI NIH HHS CA21115NCI NIH HHS CA60100NCI NIH HHS CA62924NCI NIH HHS P50 CA062924NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA023318
6 · The paper itself

Abstract

backgroundAdjuvant chemotherapy improves survival among patients with stage III colon cancer, but no reliable molecular predictors of outcome have been identified.

methodsWe evaluated loss of chromosomal material (also called loss of heterozygosity or allelic loss) from chromosomes 18q, 17p, and 8p; cellular levels of p53 and p21(WAF1/CIP1) proteins; and microsatellite instability as molecular markers. We analyzed tumor tissue from 460 patients with stage III and high-risk stage II colon cancer who had been treated with various combinations of adjuvant fluorouracil, leucovorin, and levamisole to determine the ability of these markers to predict survival.

resultsLoss of heterozygosity at 18q was present in 155 of 319 cancers (49 percent). High levels of microsatellite instability were found in 62 of 298 tumors (21 percent), and 38 of these 62 tumors (61 percent) had a mutation of the gene for the type II receptor for transforming growth factor beta1 (TGF-beta1). Among patients with microsatellite-stable stage III cancer, five-year overall survival after fluorouracil-based chemotherapy was 74 percent in those whose cancer retained 18q alleles and 50 percent in those with loss of 18q alleles (relative risk of death with loss at 18q, 2.75; 95 percent confidence interval, 1.34 to 5.65; P=0.006). The five-year survival rate among patients whose cancer had high levels of microsatellite instability was 74 percent in the presence of a mutated gene for the type II receptor for TGF-beta1 and 46 percent if the tumor did not have this mutation (relative risk of death, 2.90; 95 percent confidence interval, 1.14 to 7.35; P=0.03).

conclusionsRetention of 18q alleles in microsatellite-stable cancers and mutation of the gene for the type II receptor for TGF-beta1 in cancers with high levels of microsatellite instability point to a favorable outcome after adjuvant chemotherapy with fluorouracil-based regimens for stage III colon cancer.

Indexed as

Chromosomes, Human, Pair 18Loss of HeterozygosityMicrosatellite RepeatsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemotherapy, AdjuvantChromosomes, Human, Pair 17Chromosomes, Human, Pair 8Colonic NeoplasmsDisease-Free SurvivalFemaleFluorouracilGenetic MarkersHumansMaleBiomarkers, TumorFluorouracilGenetic MarkersTransforming Growth Factor beta

Identifiers

PMID11309634
PMCPMC3584633
OpenAlexW1976738458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.